Chemotherapy and radiation therapy (RT) is the therapy of choice for patients with locally advanced, inoperable non-small cell lung cancer (with an expected 4-year survival rate of 21% for radiation doses to 60 Gy given with concurrent chemotherapy in patients with good performance status and minimal weight loss, as established by Radiation Therapy Oncology Group (RTOG) 9410. While a minimal tumor dose of 60 Gy has been considered "standard" for the past 30 years, this dose is insufficient to control local disease. For patients receiving RT alone or radiation following induction chemotherapy, data from RTOG 9311 established that doses of 83.8 Gy using 3-dimensional conformal RT techniques were tolerable, with excess mortality observed at 90.3 Gy. When concurrent chemotherapy and 3-dimensional conformal RT are used, the maximum tolerated dose of radiation is reduced, and current indications suggest that the maximum tolerated dose in this setting is in the range of 70 to 74 Gy.

中文翻译：

---

放射治疗肿瘤学组内非小细胞肺癌的放射剂量递增试验综述。

化学疗法和放射疗法（RT）是局部晚期不可手术的非小细胞肺癌患者的首选治疗方法（对于60 Gy的放射剂量，并发化疗的患者，其4年生存率预计为21％）放射治疗肿瘤学小组（RTOG）9410确立了良好的工作状态和最小的体重减轻。尽管在过去30年中将60 Gy的最小肿瘤剂量视为“标准”剂量，但该剂量不足以控制局部疾病。 RTOG 9311的数据表明，单独接受放疗或接受放化疗后放疗的患者，使用3D立体保形RT技术可耐受83.8 Gy的剂量，在90.3 Gy时可观察到额外的死亡率。最大耐受辐射剂量降低了，目前的迹象表明在这种情况下最大耐受剂量在70至74 Gy的范围内。